Novavax receives CMA from European Commission

By The Science Advisory Board staff writers

December 22, 2021 -- Novavax announced that the European Commission (EC) has granted the company a conditional marketing authorization (CMA) for its Nuvaxovid COVID-19 vaccine for use in individuals age 18 and older. The CMA applicable in all 27 European Union member states.

According to the company, in two phase 3 clinical trials, NVX-CoV2373, Novavax's COVID-19 vaccine candidate, demonstrated high efficacy and an acceptable safety and tolerability profile. Novavax and the EC announced an advance purchase agreement in August 2021 in which the EC would purchase up to 200 million doses. The vaccine is also currently under review by multiple regulatory agencies worldwide.

Copyright © 2021
To access all The ScienceBoard content create a free account now:

Email Address:  

First Name:

Last Name:

Learn about ScienceBoard

Get the latest life sciences research and industry news, delivered straight to your inbox, for free.

Why subscribe?

ScienceBoard is uniquely focused on the business of research, addressing the biggest problems that the biomedical industry face. You’ll get breaking news, events coverage, and deep dives into the science that drives innovation, delivered to your inbox daily.

Letter from the Editor Please send me twice-weekly roundups of all the latest life research and industry news.
SAB Announcements Please send me the latest announcements from The Science Advisory Board and their partners.
Spotlight Receive notifications about new content, services, or educational resources designed to help you sharpen your skills and grow professionally.
I have read and agree to the privacy policy and terms of service and wish to opt-in for

Already have an account? Sign in here